KAHR’s lead product, KAHR-101, is
in pre-clinical development and shows great promise in the treatment of cancer
and autoimmune diseases in multiple animal models.
TSCPs are fusion proteins with two functional ends and are the first class of drugs capable of converting trans-cellular signals.
KAHR has licensed the TSCP technology from the University of Pennsylvania and selected four molecules for drug development. KAHR’s intellectual property covers a vast number of TSCP molecules, each directed at multiple cancer and autoimmune indications.
The TSCP technology has been studied for a decade, mostly at the University of Pennsylvania and the Hadassah Medical Center, and its therapeutic promise has been documented in multiple scientific publications.For KAHR-101, the company has developed a complete production process and has demonstrated its mode-of-action and clear efficacy in animal models of liver and renal cancer, multiple sclerosis (MS), and rheumatoid arthritis (RA). KAHR-101 is set for clinical development and KAHR plans a Phase-I/II trial in cancer patients at the Hadassah Medical Center.